Genomic Testing for Mental Health Medications

---

Genomic testing for mental health medications is a type of personalized medicine that aims to help clinicians choose the best medication and dosage for each patient based on their genetic makeup. In this article, we will explore the following aspects of this emerging field:

• How much it costs
• How reliable it is
• Where you can have it done
• Pros of doing it
• Cons of doing it
• Conclusion

The cost of genomic testing for mental health medications varies depending on the provider, the number of genes and drugs tested, and the insurance coverage. Some examples of providers and their prices are:

• GeneSight: $1,569 for a test that analyzes 12 genes and 57 medications 1
• Genomind: $399 for a test that analyzes 24 genes and over 130 medications 2
• Genesight: $199 for a test that analyzes one gene (MTHFR) and its impact on folate metabolism 2

Some insurance companies may cover part or all of the cost of genomic testing, depending on the patient’s diagnosis, treatment history, and plan benefits. Patients should check with their insurance provider before ordering a test to confirm their eligibility and out-of-pocket expenses.

The reliability of genomic testing for mental health medications depends on several factors, such as the quality of the test, the validity of the scientific evidence, the interpretation of the results, and the clinical application of the recommendations.

The quality of the test refers to how accurately and consistently it measures the genetic variations that affect drug response. Most tests use either blood samples or cheek swabs to collect DNA, which are then analyzed by a laboratory using advanced technologies. The precision of these methods is generally high, but errors can occur due to human or technical factors.

However, other studies have shown mixed or negative results, such as no difference or worse outcomes compared to standard care 5.

The interpretation of the results refers to how the test translates the genetic information into actionable recommendations for medication selection and dosing. Most tests use a color-coded system to categorize drugs into green (use as directed), yellow (moderate gene-drug interaction), or red (significant gene-drug interaction) groups. Some tests also provide additional information on drug mechanisms, metabolism, side effects, and FDA warnings. However, these classifications are not definitive or prescriptive, as they are based on complex and sometimes conflicting data from multiple sources. Clinicians should use their clinical judgment and experience to weigh the benefits and risks of each medication option for each patient.

The clinical application of the recommendations refers to how the test influences the actual prescribing decisions and outcomes for patients. The test is intended to be an adjunct tool to assist clinicians in optimizing treatment plans, not to replace their expertise or override their preferences. Clinicians should also consider other factors that affect drug response, such as age, weight, gender, ethnicity, medical history, co-morbidities, drug interactions, lifestyle habits, preferences, and goals. Patients should also be involved in shared decision-making and informed consent processes before starting or changing any medication.

Genomic testing for mental health medications can be done in various settings, such as:

• In a clinician’s office: Some clinicians may offer genomic testing as part of their practice or refer patients to a nearby laboratory or pharmacy that provides the service. Patients may need to make an appointment and provide a blood sample or a cheek swab at the office.
• At home: Some providers may allow patients to order genomic testing online and receive a kit that they can use to collect their DNA sample at home. Patients may need to register online and pay by credit card or insurance before receiving the kit. They may also need to mail back their sample to the provider or drop it off at a designated location.
• At a pharmacy: Some pharmacies may partner with genomic testing providers and offer their service as an over-the-counter product or a prescription fill. Patients may need to visit the pharmacy and purchase the kit or present their prescription. They may also need to provide their DNA sample at the pharmacy or at home.

Genomic testing for mental health medications may have several potential benefits for patients and clinicians, such as:

• Reducing trial-and-error: Genomic testing may help identify medications that are more likely to work or cause fewer side effects for each patient based on their genetic profile. This may reduce the need for multiple medication trials that can be costly, time-consuming, frustrating, and risky.
• Improving outcomes: Genomic testing may help improve the effectiveness and safety of treatment by enhancing symptom relief, increasing remission rates, decreasing adverse events, improving adherence, and enhancing quality of life.
• Empowering patients: Genomic testing may help empower patients to be more involved and informed in their treatment decisions. Patients may gain more insight into their condition, their medication options, and their personal preferences. They may also feel more confident and hopeful about their treatment and recovery.

Genomic testing for mental health medications may also have some potential drawbacks or limitations for patients and clinicians, such as:

• Costing money: Genomic testing may be expensive and not covered by insurance for some patients. Patients may have to pay out-of-pocket or seek financial assistance to afford the test. They may also have to pay for additional costs associated with medication changes, such as co-pays, deductibles, or prior authorizations.
• Lacking evidence: Genomic testing may not be supported by enough or consistent scientific evidence to prove its clinical utility and effectiveness. The test may not be validated by independent or regulatory agencies, such as the FDA. The test may also not account for all the genetic and non-genetic factors that influence drug response.
• Causing confusion: Genomic testing may cause confusion or misunderstanding for patients and clinicians. The test results may be complex or ambiguous to interpret and apply. The test results may also conflict with other sources of information or recommendations, such as clinical guidelines, expert opinions, or patient preferences.
• Raising ethical issues: Genomic testing may raise ethical issues related to privacy, confidentiality, consent, disclosure, discrimination, or stigma. Patients may have concerns about who has access to their genetic information, how it is stored, used, or shared, and what are their rights and responsibilities. Patients may also face challenges in communicating their test results to others, such as family members, employers, insurers, or researchers.

Genomic testing for mental health medications is a promising but controversial field that aims to personalize treatment based on genetic variations that affect drug response. The test may offer some benefits for patients and clinicians, such as reducing trial-and-error, improving outcomes, and empowering patients. However, the test may also pose some challenges or risks for patients and clinicians, such as costing money, lacking evidence, causing confusion, and raising ethical issues. Therefore, genomic testing for mental health medications should be used with caution and in conjunction with other sources of information and guidance. Patients and clinicians should discuss the pros and cons of genomic testing before deciding whether to pursue it or not.